Philip Tagari switch­es Am­gen's dis­cov­ery lab for in­sitro's ma­chine learn­ing tools; CEO Joaquin Du­a­to to chair J&J's board

In Feb­ru­ary, Philip Tagari will take a few days of re­tire­ment and then im­me­di­ate­ly re­turn to in­dus­try. He won’t be lead­ing the ther­a­peu­tics dis­cov­ery unit for a large bio­phar­ma, though.

He’ll trade in his Am­gen hat for chief sci­en­tist at a ma­chine learn­ing start­up that has reeled in hun­dreds of mil­lions in cap­i­tal to lay the ground­work for a much-hyped new mod­el of drug dis­cov­ery that aims to speed up the time to new clin­i­cal as­sets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.